Last updated on December 2017

A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial


Brief description of study

A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial

Detailed Study Description

This study is a multi-center, randomized, double blind, placebo-controlled dose-response study designed to evaluate VF-001-DP as an adjunct to SC, versus Placebo and SC in the treatment of chronic VLUs. The SC therapy for VLUs is a moisture retentive ulcer dressing and multi-layer compression therapy. Mepitel® and Coban2® have been chosen to be used as SC in this study.

The study will have three (3) phases: Screening (2 weeks), Treatment Phase (13 weeks, with treatment up to 12 weeks) and Follow-Up (12 weeks).

Only patients whose study ulcer does not exhibit more than 30% change (increase or decrease) in ulcer size post-debridement between Screening Phase Visit (S1) and Treatment Phase Visit (T1) and who continue to meet eligibility criteria at T1 will be randomized to receive either the Active Treatment (VF001-DP low or high dose plus SC) or the Control Treatment (Placebo plus SC) in a ratio of 1:1:1.

Clinical Study Identifier: TX146476

Contact Investigators or Research Sites near you

Start Over

Merlin Huici

Spotlight Research Center
Miami, FL USA
3.38miles
  Connect »

Alietta Espinosa

University of Miami Hospital
Miami, FL USA
3.38miles
  Connect »

Maria Swartz

Barry University School of Podiatric Medicine
Miami, FL USA
3.38miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.